Alps Advisors Inc. purchased a new position in shares of Amarin Co. plc (NASDAQ:AMRN) during the fourth quarter, Holdings Channel reports. The firm purchased 300,068 shares of the biopharmaceutical company’s stock, valued at approximately $1,203,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Neuberger Berman Group LLC acquired a new position in Amarin during the third quarter worth about $350,000. Alkeon Capital Management LLC acquired a new position in Amarin during the third quarter worth about $7,875,000. Cubist Systematic Strategies LLC acquired a new position in Amarin during the third quarter worth about $226,000. University of Notre Dame DU Lac acquired a new position in Amarin during the third quarter worth about $2,814,000. Finally, TD Asset Management Inc. acquired a new position in Amarin during the third quarter worth about $285,000. Hedge funds and other institutional investors own 40.14% of the company’s stock.

AMRN has been the topic of a number of recent research reports. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Zacks Investment Research downgraded shares of Amarin from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. BidaskClub raised shares of Amarin from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine raised shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Amarin in a research note on Thursday, November 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.75.

In other news, insider John F. Thero bought 10,000 shares of Amarin stock in a transaction on Thursday, November 30th. The shares were bought at an average cost of $3.24 per share, with a total value of $32,400.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steven B. Ketchum sold 135,205 shares of Amarin stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $4.41, for a total transaction of $596,254.05. The disclosure for this sale can be found here. Insiders have sold 426,720 shares of company stock worth $1,814,296 over the last ninety days. 3.72% of the stock is owned by insiders.

Amarin Co. plc (NASDAQ:AMRN) opened at $3.48 on Friday. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63. Amarin Co. plc has a 52 week low of $2.85 and a 52 week high of $4.60. The company has a market cap of $939.95, a PE ratio of -12.89 and a beta of 0.50.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/10/alps-advisors-inc-purchases-shares-of-300068-amarin-co-plc-amrn.html.

Amarin Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.